Prosecution Insights
Last updated: November 20, 2026
Application No. 17/982,399

SYSTEMS AND METHODS FOR MULTI-LABEL CANCER CLASSIFICATION

Non-Final OA §101§112§DOUBLEPATENT
Filed
Nov 07, 2022
Priority
May 14, 2019 — provisional 62/847,859 +4 more
Examiner
MINCHELLA, KAITLYN L
Art Unit
1685
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Tempus AI Inc.
OA Round
1 (Non-Final)
27%
Grant Probability
At Risk
1-2
OA Rounds
4m
Est. Remaining
48%
With Interview

Examiner Intelligence

Grants only 27% of cases
27%
Career Allowance Rate
45 granted / 167 resolved
-33.1% vs TC avg
Strong +21% interview lift
Without
With
+20.7%
Interview Lift
resolved cases with interview
Typical timeline
4y 5m
Avg Prosecution
56 currently pending
Career history
232
Total Applications
across all art units

Statute-Specific Performance

§101
31.3%
-8.7% vs TC avg
§103
23.5%
-16.5% vs TC avg
§102
6.7%
-33.3% vs TC avg
§112
29.8%
-10.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 167 resolved cases

Office Action

§101 §112 §DOUBLEPATENT
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant's election with traverse of the species of cancer conditions of differentiating between one or more sarcomas with carcinoma morphological features or protein expressions and one or more carcinomas with sarcoma morphological features or protein expressions (Species E), in the reply filed on 07 Sept. 2026 is acknowledged. After further consideration, the election requirement in the Office action mailed 05 June 2026 is withdrawn because a search burden does not exist. Status of Claims Claims 105-124 are pending. Claims 105-124 are rejected. Claims 114-115 are objected to. Priority Applicant’s claim for the benefit of a prior-filed application, U.S. Nonprovisional App. No. 15/930,234 filed 12 May 2020, U.S. Provisional App. Nos. 62/983488 filed 28 Feb. 2020, 62/902,950 filed 19 Sept. 2019, 62/855,750 filed 31 May 2019, and 62/847,859 filed 14 May 2019 under 35 U.S.C. 119(e) or under 35 U.S.C. 120, 121, 365(c), or 386(c) is acknowledged. Accordingly, the effective filing date for the instant application is 14 May 2019. Information Disclosure Statement The information disclosure statement(s) (IDS) submitted on 08 Nov. 2020, 23 June 2023, 01 July 2024, 25 Feb. 2025 are in compliance with the provisions of 37 CFR 1.97. Accordingly, the list of cited references was considered in full by the examiner. Drawings The drawings received 07 Nov. 2022 are objected to because FIG. 4A, FIG. 4B, FIG. 5A-C, FIG. 5E-F, FIG. 6A-B, FIG. 8A-B, FIG. 9, FIG. 10B, FIG. 10E, FIG. 11A-D, FIG. 12A-B, FIG. 13, FIG. 15A-C, FIG. 16, FIG. 17A, FIG. 18, FIG. 19A-19B, FIG. 20, FIG. 21A-C, and FIG. 27 are executed in color. Furthermore, the petition to accept color drawings filed 07 Nov. 2022 was dismissed in the petition decision filed 24 April 2023. Color photographs and color drawings are not accepted in utility applications unless a petition filed under 37 CFR 1.84(a)(2) is granted. Any such petition must be accompanied by the appropriate fee set forth in 37 CFR 1.17(h), one set of color drawings or color photographs, as appropriate, if submitted via the USPTO patent electronic filing system or three sets of color drawings or color photographs, as appropriate, if not submitted via the via USPTO patent electronic filing system, and, unless already present, an amendment to include the following language as the first paragraph of the brief description of the drawings section of the specification: The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee. Color photographs will be accepted if the conditions for accepting color drawings and black and white photographs have been satisfied. See 37 CFR 1.84(b)(2). Claim Objections Claims 114-115 are objected to because of the following informalities: Claims 114-115 recite “…sequence reads was generated…”. To increase clarity and use consistent language, claims 114-115 should be amended to recite “sequence reads are generated…”, given independent claim 105 actively recites sequencing the DNA and mRNA molecules. Appropriate correction is required. Claim Interpretation Claim 116 recites “wherein the ensemble classifier is trained by a method comprising: obtaining…; training…; training…; calculating…; identifying…; and re-training…”. Claim 105, from which claim 116 depends, recites “evaluating the plurality of features using an ensemble classifier…wherein the ensemble classifier uses the plurality of features to form:…(b) a determination of the cancer condition…”. Thus, claim 105 utilizes an already trained ensemble classifier model and does not require a step of actively training the ensemble classifier. As a result, the wherein clause regarding training the classifier of claim 116 is interpreted to be a product by process limitation which defines the process in which the ensemble classifier used in claim 105 was previously trained. However, claim 116 does not require the method further comprises training the ensemble classifier according to the recited method. "[E]ven though product-by-process claims are limited by and defined by the process, determination of patentability is based on the product itself. The patentability of a product does not depend on its method of production. If the product in the product-by-process claim is the same as or obvious from a product of the prior art, the claim is unpatentable even though the prior product was made by a different process." In re Thorpe, 777 F.2d 695, 698, 227 USPQ 964, 966 (Fed. Cir. 1985). See MPEP 2113. I. Claim 117 further limits the process in which the ensemble classifier was previously trained in claim 116, and therefore, the limitation of claim 117 is part of the product by process limitation of claim 116 discussed above. Claim Rejections - 35 USC § 112(b) The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. Claims 105-124 are rejected under 35 U.S.C. 112(b) as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor regards as the invention. Claim 105, and claims dependent therefrom, are indefinite for recitation of “each RNA expression feature….for the reference human transcriptome” and “each DNA feature…of the reference human genome”. Claim 105 previously recites “a reference construct for a human genome” and “a reference construct for a human transcriptome”, which encompasses any construct “for a human transcriptome” or “for a human genome” (e.g. a reference segment of the human genome), but does not recite a reference human transcriptome or a reference human genome. Therefore, it is not clear if “the reference human transcriptome” and “the reference human genome” are intended to refer to the reference constructs for the human transcriptome and human genome respectively, or if these are not the same claim element. If Applicant does not intend for the reference transcriptome and reference genome to be referring to the respective reference constructs, then it is further unclear which reference transcriptome and reference genome (e.g. hg19, hg38, etc.) is being referenced by “the reference human transcriptome” and “the reference human genome”. It is noted claims 110-112 and claim 113 also refer to “the reference human genome” and “the reference human transcriptome” respectively, and are therefore indefinite for the same reason discussed above for claim 105. For purpose of examination, “the reference human transcriptome” and “the reference human genome” are interpreted to refer to the respective reference constructs. Claim 107 is indefinite for recitation of “the first reference genome” in line 4. There is insufficient antecedent basis for this limitation in the claim because claim 105, from which claim 107 depends, recites “a reference construct for a human genome” and “the reference genome”, but does not recite “a first reference genome”. As a result, it is not clear if the first reference genome is referring to the reference construct for a human genome/the reference genome, or if this is a separate reference genome. For purpose of examination, the first reference genome is interpreted to refer to the reference construct for the human genome. Claims 107, 108, and 109, and claims dependent therefrom, are indefinite for recitation of “the sequencing information”. There is insufficient antecedent basis for “the sequencing information” in the claims because claim 105 does not recite “sequencing information”. Instead, claims 105, from which these claims depend, recites “sequencing a plurality of DNA molecules…” and “sequencing a plurality of mRNA molecules…” and furthermore identifies a plurality of features from the sequenced reads including “RNA expression features” and “DNA features”. As a result, it is not clear if “the sequencing information” is referring to the obtained “first plurality of sequence reads of DNA”, “the second plurality of sequence reads of RNA”, identified RNA expression or DNA features from the aligned reads of the RNA and/or DNA, or if this is referring to some other sequencing information. Clarification is requested via claim amendment. For purpose of examination, the limitations will be interpreted to mean “a corresponding abundance of sequence reads that map to the respective target region”. Claim 116, and dependent claim 117, are indefinite for recitation of “training, for each respective classifier in the set of intermediate classifiers,…(i) a respective subset of features in the three or more subsets of features”. There is insufficient antecedent basis for “the three or more subsets of features” in the claim because claim 105, from which claim 116 depends, recites “wherein the plurality of features comprises a first subset of features…and a second subset of features…” (i.e. the plurality of features comprises two subsets of features). However, claim 105 does not require the plurality of features include three or more subsets of features. For purpose of examination, “the three or more subsets of features” is interpreted to refer to the first and second subsets of features. Claim Rejections - 35 USC § 101 35 U.S.C. 101 reads as follows: Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title. Claims 105-124 are rejected under 35 U.S.C. 101 because the claimed invention is directed to one or more judicial exceptions without significantly more. The Supreme Court has established a two-step framework for this analysis, wherein a claim does not satisfy § 101 if (1) it is “directed to” a patent-ineligible concept, i.e., a law of nature, natural phenomenon, or abstract idea, and (2), if so, the particular elements of the claim, considered “both individually and as an ordered combination,” do not add enough to “transform the nature of the claim into a patent-eligible application.” Elec. Power Grp., LLC v. Alstom S.A., 830 F.3d 1350, 1353 (Fed. Cir. 2016) (quoting Alice, 134 S. Ct. at 2355). Applicant is also directed to MPEP 2106. Step 1: The instantly claimed invention (claim 105 being representative) is directed to a method for cancer diagnosis. Therefore, the instantly claimed invention falls into one of the four statutory categories. [Step 1: YES] Step 2A: First it is determined in Prong One whether a claim recites a judicial exception, and if so, then it is determined in in Prong Two if the recited judicial exception is integrated into a practical application of that exception. Step 2A, Prong 1: Under the MPEP § 2106.04, the Step 2A (Prong 1) analysis requires determining whether a claim recites an abstract idea, law of nature, or natural phenomenon. Claim 105 recites the following steps which fall under the mathematical concepts and/or mental processes groupings of abstract ideas: aligning each respective sequence read in the first plurality of sequence reads to a reference construct for a human genome, thereby generating a corresponding first plurality of aligned sequence reads; aligning each respective sequence read in the second plurality of sequence reads to a reference construct for a human transcriptome, thereby generating a corresponding second plurality of aligned sequence reads; identifying a plurality of features from the first plurality of aligned sequence reads and second plurality of aligned sequence reads, collectively, wherein the plurality of features comprises a first subset of features comprising RNA expression features and a second subset of features comprising DNA features, wherein each RNA expression feature is associated with an expression level of a respective target region of the reference human transcriptome and represents a corresponding abundance of sequence reads in the second plurality of aligned sequence reads, that map to the respective target region of the reference construct for the human transcriptome; and each DNA feature is associated with a respective allele status in a respective target region of the reference human genome and represents a corresponding abundance of sequence reads with a corresponding reference or variant allele, in the first plurality of aligned sequence reads, that map to the respective target region of the reference construct for the human genome; evaluating the plurality of features using an ensemble classifier comprising (i) a set of intermediate classifiers that includes a first classifier and a second classifier and (ii) a final classifier, wherein: the ensemble classifier uses the plurality of features to form a corresponding intermediate prediction for each respective classifier in the set of intermediate classifiers thereby forming a plurality of intermediate predictions, and from the plurality of intermediate predictions, a determination of the cancer condition of the subject by: obtaining a first intermediate prediction in the plurality of intermediate predictions, from among a first plurality of predictions for the cancer condition associated with the first classifier, by providing the first subset of features from the identified plurality of features as inputs to the first classifier; obtaining a second intermediate prediction in the plurality of intermediate predictions, from among a second plurality of predictions for the cancer condition associated with the second classifier, by providing the second subset of features from the identified plurality of features as inputs to the second classifier; combining, at the final classifier, a plurality of intermediate predictions that includes the first and second intermediate predictions to identify the cancer condition for the subject, wherein the determination of the cancer condition of the subject formed by the ensemble classifier comprises differentiating between general sarcomas, ependymoma, ewing sarcoma, gliosarcoma, leiomyosarcoma, meningioma, mesothelioma, and Rosai-Dorfman. The identified claim limitations falls into the groups of abstract ideas of mathematical concepts, and/or mental processes for the following reasons. In this case, aligning sequence reads to a reference construct for a human genome and human transcriptome encompasses anyway of comparing reads to sequences of a reference construct, and thus recites a mental process analogous to the claims to "comparing BRCA sequences and determining the existence of alterations," where the claims cover any way of comparing BRCA sequences such that the comparison steps can practically be performed in the human mind, University of Utah Research Foundation v. Ambry Genetics, 774 F.3d 755, 763, 113 USPQ2d 1241, 1246 (Fed. Cir. 2014). Identifying a plurality of features from the obtained first and second plurality of aligned sequence reads including RNA features and DNA features associated with a target region and representing an abundance of sequence reads amounts to a mere analysis of data involving determining read counts associated with particular target regions of a transcriptome or genome. Furthermore, evaluating the plurality of features using an ensemble classifier including a first and second classifier and a final classifier by providing a respective subset of features to a first and second intermediate classifier, and then generating intermediate predictions from the two classifiers involves inputting values into an equation and outputting a result based on the equation, which can be practically performed in the mind or with pen and paper. Then, combining a plurality of intermediate predictions including the three predictions at the final classifier to identify the diagnosis involves inputting the individual predictions into a final equation (e.g. classifier) to determine the cancer condition, which can be practically performed in the mind. Therefore, these limitations recite a mental process. Furthermore, the steps of evaluating the plurality of features using an ensemble classifier by obtaining a first and second intermediate prediction by providing a first and second subset of features to a first and second classifier, respectively, and then combining the plurality of intermediate predictions including the first and second intermediate predictions, also fall under the mathematical concept grouping of abstract ideas. The broadest reasonable interpretation of a classifier includes embodiments such as a linear regression classifier, as disclosed in Applicant’s specification at para. [00160]). Inputting features into linear regression classifiers and generating a prediction using the classifiers requires the addition of weighted features to generate the classification results, which amounts to a textual equivalent to performing mathematical calculations. Therefore, these limitations recite a mathematical concept. Dependent claims 106-113 and 116-124 further recite an abstract idea and/or are part of the abstract idea identified above. Claim 106 further recites the mental process and mathematical concept of scaling each intermediate prediction based at least in part on a respective confidence level in each respective prediction and generating a combined prediction based on the scaled predictions. Dependent claims 107-112 each further limit the mental process and/or mathematical concept of determining additional features from sequence reads and making an additional intermediate prediction using the respective features, using an additional intermediate classifier with the additional features as input into the additional classifier. Dependent claim 113 further limits the mental process of determining RNA expression features to determine features representing 10 or more of the recited genes. Dependent claims 116-117 recite the process in which the ensemble classifier was previously trained, and therefore is part of the abstract idea of using the ensemble classifier discussed in claim 105 above. Dependent claims 118-123 further limits the abstract idea of using the ensemble classifier to differentiate between the recited cancer types, and therefore is part of the abstract idea of claim 105 above. Dependent claim 124 further recites the mental process of receiving (e.g. reading) subject information comprising clinical events and differentiating the cancer condition between a new tumor and a recurrent tumor based on the clinical events. Claims 105-124 further recite the law of nature of a natural correlation between the presence of DNA alleles and RNA expression in a tumor sample of a subject and the specific cancer type of the subject, analogous to a correlation between the presence of myeloperoxidase in a bodily sample (such as blood or plasma) and cardiovascular disease risk, Cleveland Clinic Foundation v. True Health Diagnostics, LLC, 859 F.3d 1352, 1361, 123 USPQ2d 1081, 1087 (Fed. Cir. 2017) Therefore, claims 105-124 recite an abstract idea and/or law of nature. [Step 2A, Prong 1: YES] Step 2A: Prong 2: Under the MPEP § 2106.04, the Step 2A, Prong 2 analysis requires identifying whether there are any additional elements recited in the claim beyond the judicial exception(s), and evaluating those additional elements to determine whether they integrate the exception into a practical application of the exception. This judicial exception is not integrated into a practical application for the following reasons. Claims 106-113 and 116-124 do not recite any elements in addition to the judicial exception and therefore are part of the judicial exception. The additional elements of claims 105 and 114-115 include: sequencing a plurality of DNA molecules from a sample of a somatic tumor from the subject, thereby obtaining a first plurality of sequence reads of DNA from a somatic tumor of the subject; sequencing a plurality of mRNA molecules from the sample of the somatic tumor from the subject, thereby obtaining a second plurality of sequence reads of RNA from the somatic tumor of the subject; wherein the first plurality of sequence reads was generated by low pass, whole genome sequencing (claim 114); and wherein the second plurality of sequence reads generated from sequencing of cDNA (claim 115). Sequencing a tumor sample to obtain DNA and mRNA sequence reads only serves to collect data for use by the abstract idea (e.g. for identifying features that are later used in the classifiers), which amounts to insignificant extra-solution activity and does not integrate the recited judicial exception into a practical application. See MPEP 2106.05(g). Therefore, the additionally recited elements amount to insignificant extra-solution activity and, as such, the claims as a whole do no integrate the abstract idea and law of nature into practical application. Thus, claims 105-124 are directed to an abstract idea. [Step 2A, Prong 2: NO] Step 2B: In the second step it is determined whether the claimed subject matter includes additional elements that amount to significantly more than the judicial exception. See MPEP § 2106.05. The claims do not include any additional steps appended to the judicial exception that are sufficient to amount to significantly more than the judicial exception. Claims 106-113 and 116-124 do not recite any elements in addition to the judicial exception and therefore are part of the judicial exception. The additional elements of claims 105 and 114-115 include: sequencing a plurality of DNA molecules from a sample of a somatic tumor from the subject, thereby obtaining a first plurality of sequence reads of DNA from a somatic tumor of the subject; sequencing a plurality of mRNA molecules from the sample of the somatic tumor from the subject, thereby obtaining a second plurality of sequence reads of RNA from the somatic tumor of the subject; wherein the first plurality of sequence reads was generated by low pass, whole genome sequencing (claim 114); and wherein the second plurality of sequence reads generated from sequencing of cDNA (claim 115). Sequencing DNA molecules using low pass, whole-genome sequencing and sequencing cDNA from mRNA molecules from a sample and aligning reads to a reference genome or transcriptome is well-understood, routine, and conventional. This position is supported by Applicant’s specification at para. [0130]-[0131] which discloses that next-generation sequencing in accordance with methods described herein (e.g. low-pass whole-genome sequencing) and methods for mRNA sequencing, including reverse transcribing the mRNA prior to sequencing (i.e. cDNA is sequenced) are well known in the art. Applicant’s specification at para. [0134] further discloses any variety of alignment tools can be used for aligning reads to a reference genome or transcriptome. Furthermore, the combination of sequencing both DNA molecules and mRNA molecules is well-understood, routine, and conventional. This position is supported by Chakraborty et al (Onco-Multi-OMICS Approach: A New Frontier in Cancer Research, BioMed Research International, 2018, pg. 1-14; cited in IDS filed 08 Nov. 2022). Chakraborty et al. overviews multi-OMICS approaches to analyzing tumor samples in the field of cancer research (Abstract), which includes performing next-generation sequencing on both genomic DNA and mRNA from a tumor sample (Figure 4; pg. 12, col. 1, para. 2). Therefore, the additional elements, when considered alone and in combination with the other additional elements, are not sufficient to amount to significantly more than the recited judicial exception. Therefore, taken alone, the additional elements do not amount to significantly more than the above-identified judicial exception(s). Even when viewed as a combination, the additional elements fail to transform the exception into a patent-eligible application of that exception. Thus, the claims as a whole do not amount to significantly more than the exception itself. [Step 2B: NO] Therefore, the instantly rejected claims are not drawn to eligible subject matter as they are directed to an abstract idea (and/or natural correlation) without significantly more. For additional guidance, applicant is directed generally to the MPEP § 2106. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 105-106, 113-117, and 124 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-8 of U.S. Patent No. US 11527323 B2. Although the claims at issue are not identical, they are not patentably distinct from each other because: Reference claim 1 discloses all of the limitations of instant claim 105. It is noted that reference claim 1 is narrower in scope than instant claim 105, and therefore anticipates instant claim 105. Reference claim 2 discloses the limitation of instant claim 106. Reference claim 3 discloses the limitations of instant claim 113. Reference claims 4-5 discloses the limitations of instant claims 114-115, respectively. Reference claims 6-7 discloses the limitations of instant claims 116-117, respectively. Reference claim 8 discloses the limitation of instant claim 124. Citation of Pertinent Prior Art The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. Tao et al. (Classifying Breast Cancer Subtypes Using Multiple Kernel Learning Based on Omics Data, 2019, Genes, pg. 1-14; Pub. Date: 07 March 2019; cited in IDS filed 08 Nov. 2022; and Chittenden (Statistical Classification of High-throughput Multi-omics Cancer data on Quantum Computing Architectures, 2019, WuXiNextCODE, pg. 1-43; Pub. Date: April 2019; cited in IDS filed 08 Nov. 2022. Conclusion No claims are allowed. Claims 105-124 are free of the prior art for similar reasons as discussed in the Office action mailed 12 November 2020 in the parent Application 15/930,234. That is, the prior art does not show or suggest a multiclass classification model that differentiates between general sarcomas, ependymoma, ewing sarcoma, gliosarcoma, leiomyosarcoma, meningioma, mesothelioma, and Rosai-Dorfman. The closest prior art of record, Chittenden discloses method for classifying cancer types of a subject (pg. 7), which comprises identifying a plurality of features including mRNA expression features and DNA features (pg. 7, step (i); pg. 29) and evaluating the plurality of features using an ensemble classifier comprising a plurality of intermediate classifiers that take the features as input to generate intermediate predictions and a final classifier that combines the intermediate predictions to make a final cancer prediction across 20 different cancer types (pg. 7, e.g. 3 ensemble classifiers and mean classifier; pg. 8). Similarly Tao discloses a method for classifying a diagnosis of a cancer condition (Abstract), which comprises identifying RNA and DNA features from mRNA sequencing data and DNA methylation data (pg. 3, para. 3 to pg. 4, para. 2 ; pg. 4, para. 3; Figure 1; Figure 7-8). Tao discloses evaluating the plurality of features using an ensemble classifier comprising of intermediate classifiers, including a first, second, and third classifier (pg. 5, para. 3; Tables 3-4, e.g. 10 intermediate binary classifiers), and then integrating the multiple intermediate classifiers using a one vs. one classifier (i.e. a final classifier) to make a final cancer prediction (pg. 6, para. 2 to pg. 7, para. 1). However neither Chittenden or Tao does not disclose using such multi-omics data in an ensemble model for differentiating between general sarcomas, ependymoma, ewing sarcoma, gliosarcoma, leiomyosarcoma, meningioma, mesothelioma, and Rosai-Dorfman in particular. Inquiries Any inquiry concerning this communication or earlier communications from the examiner should be directed to KAITLYN L MINCHELLA whose telephone number is (571)272-6485. The examiner can normally be reached 7:00 - 4:00 M-Th. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Olivia Wise can be reached at (571) 272-2249. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /KAITLYN L MINCHELLA/Primary Examiner, Art Unit 1685
Read full office action

Prosecution Timeline

Nov 07, 2022
Application Filed
Nov 06, 2026
Non-Final Rejection mailed — §101, §112, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12742208
FRAGMENTATION FOR MEASURING METHYLATION AND DISEASE
3y 7m to grant Granted Sep 22, 2026
Patent 12618115
DETERMINATION OF CYTOTOXIC GENE SIGNATURE AND ASSOCIATED SYSTEMS AND METHODS FOR RESPONSE PREDICTION AND TREATMENT
4y 5m to grant Granted May 05, 2026
Patent 12569204
METHOD AND SYSTEM FOR ANALYZING GLUCOSE MONITORING DATA INDICATIVE OF A GLUCOSE LEVEL
3y 9m to grant Granted Mar 10, 2026
Patent 12494268
ENCODING/DECODING METHOD, ENCODER/DECODER, STORAGE METHOD AND DEVICE
5y 7m to grant Granted Dec 09, 2025
Patent 12431218
MULTI-PASS SOFTWARE-ACCELERATED GENOMIC READ MAPPING ENGINE
2y 7m to grant Granted Sep 30, 2025
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
27%
Grant Probability
48%
With Interview (+20.7%)
4y 5m (~4m remaining)
Median Time to Grant
Low
PTA Risk
Based on 167 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month